Cipla Ltd. Share Price

Nifty Pharma at Triangle Reference; RSI Caution

Nifty Pharma has broken out of its long triangle consolidation on the weekly chart and extended the rally. The index is now near 28,900, with a weekly high around 29,225. That is close to the measured-move reference of about 29,200 from the triangle breakout. RSI at about 73 shows strong momentum, but it is also forming a negative divergence, with price making higher highs while RSI makes lower highs. A similar setup was seen around September 2024, after which the index corrected. A negative divergence is only a caution and not a reversal signal by itself. A reversal candlestick near the top would add weight to the caution, and until then caution is the operative word. The 200-week SMA near 20,160 is far below, so the broader trend remains intact, but after a sharp advance, consolidation or profit booking would not be unusual. Heavyweights such as SUNPHARMA , Cipla, Dr. Reddy’s, Lupin and Divi’s Laboratories are worth tracking for how they behave from here. The weekly candle is still forming, so the closing structure matters. The weekly candle is still forming, so the closing structure matters. Negative RSI divergence at a pattern’s measured-move reference is a caution, not a sell signal; a reversal candlestick at the top gives it more weight. Disclaimer: This is for educational purposes only and is not investment advice. Please consult your financial advisor before making any investment decisions. SEBI Registered Research Analyst — INH000025212.

Divi’s Labs Q2 PAT jumps 64% to ₹1,127 Cr

DIVISLAB Divi’s Laboratories Limited (DIVISLAB) reported Q2FY27 net profit of ₹1,127 Cr, up 64% YoY and 25% QoQ. Revenue rose 35% YoY and 19% QoQ to ₹3,676 ***** Divi’s Laboratories Limited (DIVISLAB) reported Q2FY27 net profit of ₹1,127 Cr, up 64% YoY and 25% QoQ. Revenue rose 35% YoY and 19% QoQ to ₹3,676 Cr Operating profit stood at ₹1,566 Cr, up 76% YoY and 25% QoQ. Operating margin expanded sharply to 42.6% from 32.7% YoY and 40.7% in the previous quarter. Other income was ₹94 Cr. EPS rose 64% YoY and 25% QoQ to ₹42.49. The strong performance was driven by higher revenues and significant margin expansion. The key triggers are the 64% YoY jump in PAT to ₹1,127 Cr and the expansion of operating margin to 42.6%, alongside 35% revenue growth. This marks a strong quarterly performance for the API and custom synthesis major. Peers such as Laurus Labs, Aurobindo Pharma and Cipla may face comparison on revenue growth and margin trends. Near-term prices could react positively to the robust profit growth and margin expansion. Risks include input cost pressure, regulatory hurdles in key export markets, or slower order inflows. Competitors listed: Laurus Labs, Aurobindo Pharma, Cipla. We have no financial interest in this news.

Glenmark settles bulk of major US litigations.

Glenmark Pharmaceuticals Limited GLENMARK said the bulk of its major litigations in America are now settled. This removes a key overhang for the company. Most major litigations in the US have been settled. The resolution clears a significant uncertainty for the firm. It allows management to focus more on core operations and growth in the pharma sector. The key trigger is the settlement of the bulk of major US litigations. This may support near-term interest in the stock by reducing legal risk. Peers such as Sun Pharma, Dr. Reddy's Laboratories and Cipla could face relative comparison on litigation outcomes. Risks include any remaining cases or related costs. Competitors listed: Sun Pharma, Dr. Reddy's Laboratories, Cipla. We have no financial interest in this news.

Sensex Opens 1,250 Points Higher; Nifty Reclaims 24,300

Sensex open: It gapped up about 1,250 points (1.62%) to around 78,550 at 9:15 AM, against Wednesday’s close of 77,301.40. Nifty open: The Nifty50 opened up 1.59% at 24,341.55, against a close of 23,960.60, clearing 24,300. Streak: This follows five straight gains. The Nifty has also moved above the 200-day average zone around 23,900-24,000 that had been acting as resistance. Broad buying: The Nifty 100 rose 1.55%, the Nifty 500 1.41% and the Nifty Microcap 250 1.77%, so the rally covered large, mid and small caps. Top gainers: Shriram Finance, INDIGO and Tata Motors Passenger Vehicles led the Nifty50 gainers, with Bharat Electronics up 4.71%. Auto and financial stocks led. Top loser: TCS fell the most, down 2.52%, with Infosys and HCL Tech also under selling pressure. Other losers: ONGC fell 1.57%, Cipla 0.51% and Dr Reddy’s 0.36%. Drivers: Global equities rallied (the S&P 500 rose 1.58% overnight in a post-US-midterm relief rally), crude oil fell sharply, and FIIs bought for a fourth straight day.

Cipla: When Profits Fall, What Should Investors Learn?

Imagine a company selling medicines across markets, but its quarterly results tell a different story. Even an established pharmaceutical business can face pressure when expenses rise and revenue slows. This is what happened with! CiplaImagine a company selling medicines across markets, but its quarterly results tell a different story. Even an established pharmaceutical business can face pressure when expenses rise and revenue slows. This is what happened with CIPLA Ltd. in Q2 FY27. Net Profit: Fell 35% year-on-year to ₹877.54 crore, compared with ₹1,351.17 crore last year. Revenue: Declined slightly to ₹7,403.93 crore from ₹7,589.44 crore. Expenses: Increased to ₹6,377.75 crore from ₹6,004.86 crore. Think of a business like a household. If income falls while expenses increase, less money remains at the end. Similarly, rising expenses and lower revenue can put pressure on a company's profitability. However, one quarter alone does not define a company's future. Investors can study upcoming results, operating margins, business growth, cash flow, and management commentary to understand the broader picture. A familiar brand name does not guarantee consistent profits or stock-price growth. Understanding the reasons behind changing financial results is more useful than reacting to headlines alone. Profit declines deserve attention, but investors should examine financial trends, expenses, valuation, and future business prospects before drawing conclusions.

CIPLA: US BUSINESS AND PRODUCT PIPELINE UNDER WATCH

CIPLA is in focus as investors assess its quarterly performance across the Indian pharmaceutical market and international businesses. For pharmaceutical companies, earnings can be influenced by product launches, generic-drug competition, regulatory developments, pricing and the performance of key markets. What to monitor: - India formulation revenue growth - US business performance - Product launches and regulatory updates - Operating margins and research expenditure - Management guidance for the coming quarters My view: Cipla’s business outlook depends on maintaining domestic growth while navigating pricing and competition in international markets. Investors should assess whether revenue growth translates into sustainable profitability. The latest results and management commentary may provide a clearer view of the company’s earnings trajectory. Research disclosure : This content is for informational and research purposes only and should not be construed as personalised investment advice. Investors should conduct their own due diligence and consider their risk tolerance before making investment decisions.